143 related articles for article (PubMed ID: 25262158)
1. Elevation of the terminal complement activation products C5a and C5b-9 in ALS patient blood.
Mantovani S; Gordon R; Macmaw JK; Pfluger CM; Henderson RD; Noakes PG; McCombe PA; Woodruff TM
J Neuroimmunol; 2014 Nov; 276(1-2):213-8. PubMed ID: 25262158
[TBL] [Abstract][Full Text] [Related]
2. Complement C5a-C5aR1 signalling drives skeletal muscle macrophage recruitment in the hSOD1
Wang HA; Lee JD; Lee KM; Woodruff TM; Noakes PG
Skelet Muscle; 2017 Jun; 7(1):10. PubMed ID: 28571586
[TBL] [Abstract][Full Text] [Related]
3. Complement activation at the motor end-plates in amyotrophic lateral sclerosis.
Bahia El Idrissi N; Bosch S; Ramaglia V; Aronica E; Baas F; Troost D
J Neuroinflammation; 2016 Apr; 13(1):72. PubMed ID: 27056040
[TBL] [Abstract][Full Text] [Related]
4. The complement factor C5a contributes to pathology in a rat model of amyotrophic lateral sclerosis.
Woodruff TM; Costantini KJ; Crane JW; Atkin JD; Monk PN; Taylor SM; Noakes PG
J Immunol; 2008 Dec; 181(12):8727-34. PubMed ID: 19050293
[TBL] [Abstract][Full Text] [Related]
5. Plasma clearance of the human C5a anaphylatoxin by binding to leucocyte C5a receptors.
Oppermann M; Götze O
Immunology; 1994 Aug; 82(4):516-21. PubMed ID: 7835913
[TBL] [Abstract][Full Text] [Related]
6. Alterations in plasma complement levels after human ischemic stroke.
Mocco J; Wilson DA; Komotar RJ; Sughrue ME; Coates K; Sacco RL; Elkind MS; Connolly ES
Neurosurgery; 2006 Jul; 59(1):28-33; discussion 28-33. PubMed ID: 16823297
[TBL] [Abstract][Full Text] [Related]
7. Complement activation in relation to development of preeclampsia.
Haeger M; Unander M; Bengtsson A
Obstet Gynecol; 1991 Jul; 78(1):46-9. PubMed ID: 2047067
[TBL] [Abstract][Full Text] [Related]
8. Innate and adaptive immunity in amyotrophic lateral sclerosis: evidence of complement activation.
Sta M; Sylva-Steenland RM; Casula M; de Jong JM; Troost D; Aronica E; Baas F
Neurobiol Dis; 2011 Jun; 42(3):211-20. PubMed ID: 21220013
[TBL] [Abstract][Full Text] [Related]
9. Complement activation during liver transplantation.
Tomasdottir H; Henriksson BA; Bengtson JP; Bengtsson A; Stenqvist O; Persson H
Transplantation; 1993 Apr; 55(4):799-802. PubMed ID: 8475554
[TBL] [Abstract][Full Text] [Related]
10. Detection of activated complement complex C5b-9 and complement receptor C5a in skin biopsies of patients with systemic sclerosis (scleroderma).
Sprott H; Müller-Ladner U; Distler O; Gay RE; Barnum SR; Landthaler M; Schölmerich J; Lang B; Gay S
J Rheumatol; 2000 Feb; 27(2):402-4. PubMed ID: 10685805
[TBL] [Abstract][Full Text] [Related]
11. Vasculitis-like neuropathy in amyotrophic lateral sclerosis unresponsive to treatment.
Devigili G; Uçeyler N; Beck M; Reiners K; Stoll G; Toyka KV; Sommer C
Acta Neuropathol; 2011 Sep; 122(3):343-52. PubMed ID: 21626035
[TBL] [Abstract][Full Text] [Related]
12. Enhanced anaphylatoxin and terminal C5b-9 complement complex formation in patients with the syndrome of hemolysis, elevated liver enzymes, and low platelet count.
Haeger M; Unander M; Bengtsson A
Obstet Gynecol; 1990 Oct; 76(4):698-702. PubMed ID: 2216207
[TBL] [Abstract][Full Text] [Related]
13. Early plasma complement C3a levels correlate with functional outcome after aneurysmal subarachnoid hemorrhage.
Mack WJ; Ducruet AF; Hickman ZL; Garrett MC; Albert EJ; Kellner CP; Mocco J; Connolly ES
Neurosurgery; 2007 Aug; 61(2):255-60; discussion 260-1. PubMed ID: 17762737
[TBL] [Abstract][Full Text] [Related]
14. The complement factor C5a receptor is upregulated in NFL-/- mouse motor neurons.
Humayun S; Gohar M; Volkening K; Moisse K; Leystra-Lantz C; Mepham J; McLean J; Strong MJ
J Neuroimmunol; 2009 May; 210(1-2):52-62. PubMed ID: 19286267
[TBL] [Abstract][Full Text] [Related]
15. Alterations in systemic complement component 3a and 5a levels in patients with cerebral arteriovenous malformations.
Haque R; Hwang BY; Appelboom G; Piazza MA; Guo K; Connolly ES
J Clin Neurosci; 2011 Sep; 18(9):1235-9. PubMed ID: 21742500
[TBL] [Abstract][Full Text] [Related]
16. Lower circulating levels of complement split proteins C3a and C4a in maternal plasma of women with gestational diabetes mellitus.
Lappas M
Diabet Med; 2011 Aug; 28(8):906-11. PubMed ID: 21615487
[TBL] [Abstract][Full Text] [Related]
17. Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation.
Rinder CS; Rinder HM; Smith BR; Fitch JC; Smith MJ; Tracey JB; Matis LA; Squinto SP; Rollins SA
J Clin Invest; 1995 Sep; 96(3):1564-72. PubMed ID: 7657827
[TBL] [Abstract][Full Text] [Related]
18. Increased soluble C5b-9 in CSF of neuromyelitis optica.
Wang H; Wang K; Wang C; Qiu W; Lu Z; Hu X
Scand J Immunol; 2014 Feb; 79(2):127-30. PubMed ID: 24313854
[TBL] [Abstract][Full Text] [Related]
19. The extracellular neutral cysteine proteinase of Entamoeba histolytica degrades anaphylatoxins C3a and C5a.
Reed SL; Ember JA; Herdman DS; DiScipio RG; Hugli TE; Gigli I
J Immunol; 1995 Jul; 155(1):266-74. PubMed ID: 7602103
[TBL] [Abstract][Full Text] [Related]
20. [Atopic dermatitis. II. The status of complement proteins and the pathogenetic role of anaphylatoxins C4a, C3a and C5a].
Sergeev IuV; Reznikov IuP; Lobanova EV; Pimenova NS
Vestn Dermatol Venerol; 1989; (4):4-7. PubMed ID: 2788339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
